Haematoporphyrin Based Photodynamic Therapy Combined with Hyperthermia Provided Effective Therapeutic Vaccine Effect against Colon Cancer Growth in Mice

Yaoming He¹, Haiyan Ge¹✉, Shuping Li²

1. Department of General Surgery, Shanghai East Hospital of Tongji University, No. 150 Jimo Road, Shanghai 200120, China
2. Department of Science and Research, Shanghai East Hospital of Tongji University, No. 150 Jimo Road, Shanghai 200120, China

✉ Corresponding author: Dr. Haiyan Ge, Department of General Surgery, Shanghai East Hospital of Tongji University, No. 150 Jimo Road, Shanghai 200120, China; Tel: 0086-21-38804518; Fax: 0086-21-58798999; E-mail: gounarisl@hotmail.com; 08heyaoming@tongji.edu.cn

© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2012.07.12; Accepted: 2012.09.05; Published: 2012.09.19

Abstract

Photodynamic therapy (PDT) has become an attractive option used in tumor treatment via its direct tumoricidal activities or its immune-boosting activities. On the other hand, heat shock protein 70 has been found to be largely associated with the establishment of anti-tumor activities offered by hyperthermia treated tumor cells. In the present study, we found that injection of tumor-bearing mice with colon cancer cell line CT-26 treated with haematoporphyrin based photodynamic therapy (hematoporphyrin monomethyl ether based PDT, HMME-PDT) together with hyperthermia demonstrated the most effective therapeutic effects against tumor growth, followed by cells treated by hyperthermia alone. CT-26 cells treated only with HMME-PDT failed to provide any therapeutic effects, although significant cell death was induced by HMME-PDT. Compared to hyperthermia treatment, HMME-PDT induced more efficient surface localization of HSP70 on CT-26 cells which correlated with efficient activation of cytolytic CD8 T cells and with effective anti-tumor responses. Thus, our study demonstrated that the surface expression of HSP70 may play a more important role than the total expression or release of this molecule in the activation of immune responses. And our study offered a novel modified PDT approach to the treatment of tumor cells intrinsically low on HSP70 expression.

Key words: photodynamic therapy, HSP70, hyperthermia, cancer vaccine, hematoporphyrin monomethyl ether

Introduction

Photodynamic therapy (PDT) has been established as a new therapy for the treatment of neoplasm and other diseases (1). Distinct from traditional radiotherapy and chemotherapy, PDT possesses unique advantages. For example, it induces extranuclear generation of photooxidative cytotoxic molecules without causing genotoxic damage (2). More importantly, PDT also induces a durable anti-tumor immune response to destroy the remaining tumor cells (3), which indicates PDT is able to enhance the immunogenicity of tumor cell. And using PDT to generate a cancer vaccine is an interesting application of this modality. Several reports demonstrated PDT generated vaccine exhibited anti-tumor effect, and
some mechanisms were mentioned. For example, Gollnick used photofrin, a porphyrin-derived photosensitizer, and showed that PDT treated EMT6 tumor cells displayed protective vaccine effects against tumor growth, and the protective effects were correlated with enhanced activation of dendritic cells (4). Korbelik and his colleagues found that the BPD-PDT and Ce6-PDT could provide a therapeutic vaccine effects against SCCV II tumor. The former one was likely resulted from increased surface expression of HSP70 and complement opsonization (5), the latter one from membrane lipid alteration and cell apoptosis (6). Treatment of liver cancer cells with hematoporphyrin monomethyl (HMME), a porphyrin-derived photosensitizer, has been shown to offer some preventive vaccine effects against liver carcinoma (7). When we attempted to injection of colon cancer CT-26 cells treated with HMME-PDT, it failed to demonstrate a therapeutic vaccine effect. One of the noted differences between Korbelik’s and our study was that the SCCV II cell line they used highly expressed HSP70.

Heat shock protein 70 (HSP70), as its name indicated, is normally induced by heat stress (8). In fact, HSP70 appears to be the most studied heat shock protein towards its beneficial effects offered by heat treated tumors(9). Unlike other kinds of photosensitizers used in PDT therapy which can induce the expression of HSP70, porphyrin-derived photosensitizers seemed to be less effective in the induction of HSP70 expression (10), but tends redistribute HSP70 to cell surfaces (11) which then facilitates the development of adaptive immunity (12). Therefore, in the current study we designed a novel approach to combine hyperthermia with HMME-PDT to achieve both elevated expression of HSP70 and its enhanced surface localization on treated tumor cells in hope that improved therapeutic effects would be acquired.

Materials and Methods

Animals and tumor induction in vivo

Poorly immunogenic mouse colon carcinoma cell line CT-26 and 6-8 weeks old female Balb/c mice (host for CT-26 tumor) were used in this research. Tumor was induced via injection of $2 \times 10^6$ CT-26 cells subcutaneously on the right lower abdomen. The tumor growth was recorded based on the diameters measured with caliper and the volume of tumor was calculated with formula as volume = $0.5 \times a \times (\text{longest diameter}) \times b^2$ (the longest diameter perpendicular to $a$).

Cell treatments

CT-26 cells were cultured in 37°C and 5%CO₂ in high glucose DMEM medium. For PDT treatment, CT-26 was cultured in complete medium containing hematoporphyrin monomethyl (HMME) in different dilutions for 12 hours, and then washed with PBS for 3 times. The cells were transferred to serum free medium before being irradiated with 630nm light via semi-conductor laser at a dose of $5J/cm^2$ (ALA-PDT KDL300) for 20 min. Therefore, HMME-PDT was used to represent the PDT treatment. For PDT combined with hyperthermia abbreviated as heat-PDT, treatment of cells at 41°C was performed at the last third hour of HMME incubation. $1 \times 10^6$ PDT-treated CT-26 cells were diluted in 50μl PBS before they were used for injection. For hyperthermia stress, CT-26 cells were incubated in water bath at 41°C for 1 hour, and then incubated in normal condition for 3 hours. After cell number was evenly adjusted as that of PDT-treated cells, they were subjected to 3 cycles of freezing and thaw (at 80°C for 20 min and 37°C for 10 min) to eliminate living tumor cells, and this group is named as heat-F/T.

Immunization

Five days after tumor implantation when tumors usually reached approximate 3 mm in largest diameter, mice were immunized with differently treated cells by single subcutaneous peritumoral injection as described (5). Injected cells were generated from cells treated with HMME-PDT, heat-PDT or heat-F/T. PBS injection was used as a control. Measurement of tumor size was used to assess the therapeutic effects of various cell lysates.

For analyzing the activity of cytotoxicity T lymphocyte (CTL), normal mice were used after they were injected with $5 \times 10^5$ treated CT-26 cells by HMME-PDT, heat-PDT or heat-F/T at lower abdominal region bilaterally once a week for 3 weeks. The CTL activity was analyzed with flow cytometric analysis or with MTT assay as described below.

Flow cytometry analysis

One week after final injection, spleen and draining inguinal lymph nodes were isolated and were prepared to single-cell suspension. Draining inguinal lymph nodes cells were restimulated at $3 \times 10^6$/well on 24-well plate with PMA (40ng/ml, Sigma), ionomycin (100ng/ml, Sigma) and BFA (10μg/ml, BioLegend Inc.) for 4 hours. The cytokines expressed were examined based on intracellular cytokine staining protocol (13). Cell surface molecule was stained with APC-anti-CD8 (BioLegend Inc) and intracellular IFN-γ was stained with PE-anti-IFN-γ (BioLegend Inc), which together reflected the activation of cytotoxic lymphocytes (CTLs). Flow cytometry
was also used to analyze the expression of HSP70 on the cell surfaces (BioLegend Inc). Same class of antibody conjugated with same kind of fluorescence was used in all flow cytometry analysis as isotype control.

**MTT assay**

Splenocyte suspension generated as above was analyzed for cytolytic effects by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT), and splenocytes from normal mice were used as control. Briefly, CT-26 target cells were incubated with splenocytes in various ratios (1:10, 1:50 and 1:100) for 72 hours in 96 wells plate. MTT was added at appropriate dilution after supernatant was discarded. After incubation for 4 hours, cells were retained and DMSO was used to dissolve the lipid-soluble MTT. Cell viability was detected by microplate reader at 495nm. The activation of cytotoxic lymphocytes was calculated by the formula CTL activation=(absorbance of treatment group - absorbance of control group)/absorbance of control group × 100%. Background absorbance was subtracted from each reading. Additionally, MTT assay was also used to measure the viability of CT-26 after PDT treatment.

**Western blot**

Total cell lysates of treated cell were extracted by protein extraction kit from Beyotime Inc (China) and separated by electrophoresis on a 10% polyacrylamide gel. The protein were then transferred to PVDF membrane and incubated for 2 hours in TBS containing 10% nonfat milk. After blocking, membranes were incubated with rabbit polyclonal antibody specific for HSP70 (CST Inc) followed by incubation of HRP conjugated goat anti-rabbit IgG. The resulted blots were analyzed by ECL detection system (ImageQuant LAS 4000). The supernatants of treated cells were also collected to measure HSP70 release by western blot analysis. The experiment was repeated for three times.

**Statistical analysis**

Data comparisons were done by Student’s t test or one-way ANOVA analyses. Comparison with a difference of P < 0.05 was considered significant.

**Results**

**HMME-PDT combined with hyperthermia treatment provided the most potent therapeutic effects against CT-26 growth**

We examined if HMME-PDT would offer therapeutic effects against colon cancer and if hyperthermia modified HMME-PDT, ie, heat-PDT, would enhance the therapeutic effects of HMME-PDT. As shown in Figure 1, when tumor-bearing mice that had been implanted with CT-26 cells for approximately one week before they were injected with differentially treated cells. HMME-PDT treatment showed no significant therapeutic effects in the inhibition of tumor growth compared to PBS injection control. Up to 18 days after treated cells injection, both heat-F/T and heat-PDT treatment induced a significant tumor growth inhibition than PBS and HMME-PDT treatment. More importantly, heat-PDT treatment elicited an even more vigorous inhibition on tumor growth than heat-F/T treatment. Therefore, our finding indicated that the therapeutic vaccine effects on colon cancer cell growth by haematoporphyrin monomethyl (HMME) photosensitizer can only be established in the presence of hyperthermia treatment.

**Fig 1. Heat-PDT provided the most potent therapeutic effect against CT-26 growth.** Mice were injected with $2 \times 10^5$ CT-26 cells subcutaneously. 5 days later when tumor started to appear, mice were immunized with $1 \times 10^7$ CT-26 cells treated with HMME-PDT, Heat-PDT and Heat-F/T as described in the Methods. Mice injected with PBS were used as control. Response to the therapeutic vaccine treatment was determined by tumor volume measurement as in Methods. Each group consisted of five mice. Significance test was performed by One-way ANOVA with * representing comparison with PBS; ● with HMME-PDT and ◆ with Heat-F/T.
**HSP70 expression but not the presence of cell death was associated with the anti-tumor effects**

PDT has been shown to promote cell death at a dose-dependent manner and certain photosensitizers induce heat shock protein 70 (HSP70) expression in treated cells (10). Since these two parameters can both play important roles in initiating and boosting immunity, we examined if they contribute differently to the anti-tumor effects observed. When the irradiation condition of 5J/cm² for 20 minutes was applied, HMME-PDT induced cell death at a dose-dependent fashion as revealed by MTT assay (data not show). The induction of cell death was also consistent with the loss of β-actin detection when higher dose of HMME was applied to CT-26 cells (Figure 2). No significant expression of HSP70 was found in all the doses of HMME examined in PDT-treated cells (Figure 2).

To study the impact of hyperthermia on the induction of HSP70 in CT-26 cells, cells were incubated in various temperatures for 1 hour. We found that CT-26 cells exhibited low level of HSP70 expression at 37°C. And the level of expression was increased as temperature raised (Figure 2), reaching to peak value when the temperature reached 41°C. Taken together, these data demonstrated that the induction of HSP70 played a more relevant role in conferring the therapeutic anti-tumor vaccine effects comparing to the induction of cell death. However, the mechanisms on the supreme antitumor vaccine effect provided by heat-PDT remained to be determined.

**HMME-PDT promoted the release and surface redistribution of HSP70 induced by hyperthermia**

Although HMME-PDT failed to induce the HSP70 expression in treated CT-26 cells (Figure 2), we examined if HMME-PDT is able to affect the release or the cell surface expression of HSP70. To detect the release of HSP70, the presence of HSP70 in the supernatants of treated cells was studied at 2 hours post irradiation by western blot analysis. As shown in Figure 3, HSP70 expression was up-regulated efficiently from cells heated at 41°C, and no HSP70 was found in the supernatants if heated cells were not subjected freezing and thaw treatment (Figure 3, lane 1). Furthermore, HMME-PDT treatment induced an elevated presence of HSP70 in the supernatants at a dose-dependent manner (Figure 3), corresponding to the cell death occurred. Therefore an enhanced release of HSP70 induced by HMME-PDT was likely a result of enhanced cell death, which could occur both in heat-PDT and heat-F/T.

![Fig 2. Hyperthermia but not HMME-PDT induced HSP70 expression on CT-26 effectively.](http://www.medsci.org)
The migration of HSP70 to cell surfaces was analyzed by flow cytometric analysis. As shown in Figure 4, hyperthermia only promoted the surface migration of HSP70 slightly although it did induce the expression of this protein. In contrast, the percentage of surface HSP70 positive cells increased more significantly when CT-26 cells were treated with heat-PDT, indicating that HMME-PDT was able to promote the migration of HSP70 to the cell surfaces more efficiently than heat. Both low (10μg/ml) and high dose (30μg/ml) of HMME demonstrated this effect. No HSP70-positive cells were detected if cells were treated with HMME-PDT alone. Altogether, it is demonstrated that HMME-PDT could more efficiently promote the surface migration of HSP70 comparing to hyperthermia treatment, suggesting that the surface presence of HSP70 may exert more critical effect in the induction of anti-tumor response.

Heat-PDT promoted CTL activation

To further evaluate the most potent antitumor feature offered by heat-PDT treatment, activation of CD8 T cells was measured from mice injected with the cells treated by HMME-PDT, heat-F/T or heat-PDT. Mice treated with cells of heat-PDT, higher proportion of activated CD8 T cells in the draining inguinal lymph node were found when CTL was measured by the ability of IFN-γ production from CD8 T cells (Figure 5a). Similar finding was also obtained when CTL activities were measured by MTT assay (Figure 5b). It is indicated that this combination-based vaccine could elicit the most effective cytotoxic lymphocytes activation, corresponding well with their most potent anti-tumor therapeutic vaccine effects.

Discussion

Photodynamic therapy (PDT) is regarded as a promising therapy partly due to its reported capabilities of rapid recruitment and activation of immune cells, which in turn facilitate the development of anti-tumor adaptive immunity (14). In fact, PDT-treated tumor cells were shown to be effective in both preventive (4) and therapeutic (5) vaccines. However, in our research, no anti-tumor effect was found when cells were only treated by HMME-PDT. Two possible causes might account for this difference. SCCVII cell line investigated in Golnick’s research was a breast carcinoma that expresses high level of HSP70. However, the colon cancer cell line CT-26 used in our study expresses low level of HSP70 (Figure 3). On the other hand, Ce6 photosensitizers used in Korbelik’s research was able to induce raised HSP70 protein expression, which might contribute to its application in vaccine generation (15). However, the HMME photosensitizer used in our research failed to demonstrate this effect by itself independent of dosage. It is not known yet if the differences in their ability to induce the protein expression of HSP70 between HMME and Ce6 were due to its different subcellular locations, ie, HMME is mainly distributed in Golgi body, ER, mitochondria and lysosome (16), while ce6 is mainly found in lysosome and plasma membrane (17).
Cell death resistance and immune evasion are two important interrelated factors in tumor cell growth and metastasis (18, 19). Recently the name of immunogenic cell death was coined to define the cell death that reaches to a level which can induce both innate and adaptive immunity effectively irrespective of the form of cell death (20). Therefore, certain level of cell death is a critical endogenous alarm signal for immune system. In our study, however, although significant amount of cell death is indeed induced by HMME-PDT, no immune activation was observed. This may indicate that the quality of cell death is more relevant to the activation of immune response. Indeed, uric acid, HMGB-1, ATP, heat shock proteins and many others have been reported as effective诱导ing molecules for immune reaction, collectively called damaged associated molecular patterns (DAMPs). Thus, based on our study and published studies by others (21, 22), we predicted that the failure of offering productive activation of anti-tumor CTL response by cells treated with HMME-PDT is not due to lack of cell death, but a result of lack of HSP70 induction.

HSP70 is originally known as a chaperon protein (23). But it was also a critical DAMP. It can interact with natural killer (NK) cells and promote their activation (24). The presence of HSPs on the surface of cells can prevent the recognition of inhibitory receptor complex CD94/NKG2A on NK cells with its MHC class I ligands, facilitating to activation of NK cell and killing of HSP-positive tumor target cells (25). HSP70 also interacts with pattern-recognition receptors (PRR) on antigen-presenting cells like TLR-4, CD91, LOX-1 and CD40 to promote the release of released pro-inflammatory cytokines through the activation of NF-κB pathway (26, 27). Additionally, HSPs including HSP70 have been found to be important in the induction of cross-presentation of extracellular antigens to evoke CTL response (28). Our finding that injection of extracellular cell-associated antigens were able to induce CTL responses appeared to indicate that the cross-presentation by extracellular antigens may be largely dependent on the presence of surface HSP70.

Like all the heat shock proteins, HSP70 is an intracellular protein without signal peptide, which thus is usually not secreted. In this case, HSP70 can be released as a result of cell death (21). Alternatively, HSP70 also can be release through though an endolysosomal compartment, which was similar to one used by IL-β that without out a signal peptide (29). In our results, the release of HSP70 was increased while HMME concentration was raised and more cell death was induced. On the other hand, cells were induced to express HSP70 by hyperthermia treatment without induction of cell death, no HSP70 release was detected (Figure4). Thus, the elevated releasing of HSP70 found in HMME-PDT treated cells was more likely resulted from cell death pathway. Concerning membrane localization of HSP70, the mechanisms are not clear. It was reported that lesions in the membrane of PDT-treated cells caused the inner membrane to be flopped outward and exposed the HSP70 with proteins or lipids lining the inner leaflet of on to the plasma membrane (30, 31). Furthermore, it was thought that surface localized HSPs might have a role in their efforts to stabilize damaged membranes and preserve their integrity under the oxidative stress (32). We are not certain how HMME-PDT is able to promote the membrane localization of HSP70 at present. It could be a result of HMME-PDT induced cell damages as well, since more cell surface HSP70 was
found in HMME-PDT treated cells comparing to cells treated with hyperthermia alone, corresponding well with their different capacity of causing cell damages.

Cancer is the second cause of human death (33). Although surgery, chemotherapy and radiotherapy all achieved great successes in healing cancer, they all had their respective limitations. Immune therapy has its unique advantages, such as low toxicity, high efficacy, specific targeting and long duration, becomes a potential effective method (34). Vaccine especially therapeutic ones is one of the most attractive members in immune-related therapies. In this study, we provided a novel immune-based approach to increase the therapeutic efficacy on tumor vaccines with low intrinsic heat shock protein expressions. Furthermore, we uncovered the importance of surface localization of heat shock protein in the induction of cross-presentation and activation of cytototoxic T cells.

Acknowledgment

The study was supported by the grant of Scientific and Technological Project of Shanghai Science and Technology Commission (054119555).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Huang Z, Xu H, Meyers AD, et al. Photodynamic therapy for treatment of solid tumors—potential and technical challenges. Technol Cancer Res Treat 2008; 7: 309-320.
2. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90: 889-905.
3. Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 1996; 14: 329-334.
4. Gollnick SO, Vaughan L and Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 2002; 62: 1604-1608.
5. Korbelik M, Sun J. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother 2006; 55: 900-909.
6. Korbelik M, Stott B and Sun J. Photodynamic therapy-generated vaccines: relevance of tumour cell death expression. Br J Cancer 2007; 97: 1381-1387.
7. Zhang HY, Ma WJ, Li YX: Generation of effective vaccines against liver cancer by using photodynamic therapy. Lasers in Medical Science 2009; 24: 549-552.
8. Stott B and Korbelik M. Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy. Cancer Immunol Immunother 2007; 56: 649-658.
9. Milani V and Noessner E. Effects of thermal stress on tumor antigenicity and recognition by immune effector cells. Cancer Immunol Immunotherapy 2006; 55: 312-319.
10. Gomer CJ, Ryter SW, Ferrario A, Rucker N, Wong S, Fisher AM. Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Cancer Res 1996; 56: 2355-2360.
11. Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res 2005; 65: 1018-1026.
12. Torigoe T, Tamura Y, Sato N. Heat shock proteins and immunity: application of hyperthermia for immunomodulation. Int J Hyperthermia 2009; 25: 610-616.
13. Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods 1995; 188: 117-128.
14. Gollnick SO, Evans S6, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Brit J Cancer 2003; 88: 1772-1779.
15. Castano AP, Gad F, Zahrina T, Hamblin MR. Specific anti-tumor immune response with photodynamic therapy mediated by benzoporphyrin derivative and chlorin(6). Laser-Tissue Interaction XIV 2003; 4961: 1-9.
16. Dai W, Li X, Jing Z, Liu F, Gu Y. Dynamical Change of Intracellular Distribution of Haptenomorphin Monomethyl Ether in A549 Cells. Acta Laser Biology Sinica (CHINA) 2008; 17: 725-728.
17. Mojzisova H, Bonnie S, Vever-Bizet C and Brault D. Cellular uptake and subcellular distribution of chlorin e6 as functions of pH and interactions with membranes and lipoproteins. Biotechnica El Biophysics Acta-Biomembranes 2007; 1768: 2748-2756.
18. Blagosklonny MV. Cell immortality and hallmarks of cancer. Cell Cycle 2003; 2: 296-299.
19. Zitvogel L, Tenniere A, Kroemer G. Cancer despite immunosurveillance: immuno-escape and immunosubversion. Nat Rev Immunol 2006; 6: 715-727.
20. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 2010; 1805: 53-71.
21. Basu S, Binder RJ, Soto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NK-kappa B pathway. Inter Immunol 2000; 12: 1539-1546.
22. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Med 1998; 4: 581-587.
23. Bukaub W, Weissman J, Horwich A. Molecular chaperones and protein quality control. Cell 2006; 125: 443-451.
24. Multhoff G, Mizzen L, Winchester CC, et al. Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Int Immunol 2002; 14: 1779-1786.
25. Michaelsson J, Teixeira de Matos C, Achoru A, Lanier LL, Karre K, Soderstrom K. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 2002;196: 1403-1414.
26. Theriault JR, Mambula SS, Sawamurra T, Stevenson MA, Calderwood SK. Extracellular HSP70 binding to surface receptors present on antigen presenting cells and endothelial/epithelial cells. FEBS Lett 2005; 579: 1591-1600.
27. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002; 277: 15028-15034.
28. Nishikawa M, Takemoto S, Takakura Y. Heat shock protein derivatives for delivery of antigens to antigen presenting cells. Inter J Pharmaceut 2008; 354: 23-27.
29. Mambula SS, Calderwood SK. Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol 2006; 177: 7849-7857.
30. Frasch SC, Henson PM, Nagaoa K, Fessler MB, Borregaard N and Bratton DL. Phospholipid flip-flop and phospholipid scramblase 1 (PLSCR1) co-localize to uropod rafts in formylated neutrophils. J Biol Chem 2004; 279: 17625-17633.
31. John K, Schreiber S, Kubelt J, Herrmann A, Muller P. Transblayer movement of phospholipids at the main phase transition of lipid membranes: implications for rapid flip-flop in biological membranes. Biophys J 2002; 8: 3315-3323.
32. Zhou F, Xing D, Chen WR. Dynamics and mechanism of HSP70 translocation induced by photodynamic therapy treatment. Cancer Lett 2008; 264: 135-144.
33. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
34. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 2006; 6: 535-545.